Literature DB >> 19202351

Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins.

Luis G Bermúdez-Humarán1.   

Abstract

Food-grade lactic acid bacteria (LAB) have been safely consumed by humans for centuries in fermented foods. Lactococcus lactis, a LAB widely used in the dairy industry as a starter, can be genetically engineered to efficiently produce a large variety of proteins. This feature has been recently exploited by scientists for the development of a new generation of vectors to deliver therapeutic proteins to the mucosal tissues. The successful Phase I clinical trial with a L. lactis strain secreting interleukin-10 for Crohn's disease has opened new horizons for the use of genetically engineered LAB as delivery vehicles. This commentary reviews the current advances made with L. lactis as live vector for the mucosal delivery of therapeutic proteins.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19202351     DOI： 10.4161/hv.5.4.7553

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


  31 in total

1.  Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B.

Authors:  Han Lei; Zhina Sheng; Qian Ding; Jian Chen; Xiaohui Wei; Dominic Man-Kit Lam; Yuhong Xu
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Engineering trehalose synthesis in Lactococcus lactis for improved stress tolerance.

Authors:  Ana Lúcia Carvalho; Filipa S Cardoso; Andreas Bohn; Ana Rute Neves; Helena Santos
Journal:  Appl Environ Microbiol       Date:  2011-04-22       Impact factor: 4.792

3.  Construction of a recombinant allergen-producing probiotic bacterial strain: Introduction of a new line for a live oral vaccine against Chenopodium album pollen allergy.

Authors:  Leila Roozbeh Nasiraie; Farideh Tabatabaie; Mojtaba Sankian; Fakhri Shahidi; Abdolreza Varasteh
Journal:  Rep Biochem Mol Biol       Date:  2013-10

Review 4.  Engineering commensal bacteria for prophylaxis against infection.

Authors:  Yih-Lin Goh; HongFei He; John C March
Journal:  Curr Opin Biotechnol       Date:  2012-03-28       Impact factor: 9.740

5.  Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.

Authors:  Aniela Wozniak; Natalia Scioscia; Patricia C García; James B Dale; Braulio A Paillavil; Paulette Legarraga; Francisco J Salazar-Echegarai; Susan M Bueno; Alexis M Kalergis
Journal:  Microbiol Immunol       Date:  2018-06-11       Impact factor: 1.955

6.  Induction of immune responses in mice after oral immunization with recombinant Lactobacillus casei strains expressing enterotoxigenic Escherichia coli F41 fimbrial protein.

Authors:  Jian-Kui Liu; Xi-Lin Hou; Chun-Hua Wei; Li-Yun Yu; Xiao-Jie He; Gui-Hua Wang; Jong-Soo Lee; Chul-Joong Kim
Journal:  Appl Environ Microbiol       Date:  2009-05-15       Impact factor: 4.792

7.  Cloning and characterization of a novel tuf promoter from Lactococcus lactis subsp. lactis IL1403.

Authors:  Eun Bae Kim; Da Chuan Piao; Jee Soo Son; Yun Jaie Choi
Journal:  Curr Microbiol       Date:  2009-07-21       Impact factor: 2.188

8.  Multi-omics approach to study the growth efficiency and amino acid metabolism in Lactococcus lactis at various specific growth rates.

Authors:  Petri-Jaan Lahtvee; Kaarel Adamberg; Liisa Arike; Ranno Nahku; Kadri Aller; Raivo Vilu
Journal:  Microb Cell Fact       Date:  2011-02-24       Impact factor: 5.328

Review 9.  Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.

Authors:  Luis G Bermúdez-Humarán; Pascale Kharrat; Jean-Marc Chatel; Philippe Langella
Journal:  Microb Cell Fact       Date:  2011-08-30       Impact factor: 5.328

10.  Oral immunization with Lactococcus lactis secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine model.

Authors:  Giselli Fernandes Asensi; Nathalia Ferrari Fonseca de Sales; Fabiano Ferreira Dutra; Daniel Ferreira Feijó; Marcelo Torres Bozza; Robert G Ulrich; Anderson Miyoshi; Katia de Morais; Vasco Ariston de Carvalho Azevedo; Joab Trajano Silva; Yves Le Loir; Vânia Margaret Flosi Paschoalin
Journal:  Microb Cell Fact       Date:  2013-04-05       Impact factor: 5.328
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.